Although up to 90% of pivotal clinical trials for drugs approved for sale in the U.S. provide data on study participants by sex, race, and age, less than four in 10 provide data on ethnicity, according to a newly completed study by the Tufts Center for the Study of Drug Development that establishes benchmarks for demographic representation.   From 2007 through 2017, participation by women in pivotal Phase III clinical trials fell short of expected participation levels, based on disease prevalenc...